Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Sight Sciences develops and commercializes surgical and interventional glaucoma devices, primarily the OMNI Surgical System for micro-invasive glaucoma surgery (MIGS) and the TearCare system for dry eye disease. The company operates in the ophthalmic medical device market with a direct sales force targeting ophthalmologists and ASCs across the United States. Despite strong gross margins (85.5%), the company remains deeply unprofitable with operating losses exceeding 60% of revenue as it invests in commercial expansion and clinical development.
Sight Sciences employs a razor-razorblade model, selling capital equipment (OMNI consoles, TearCare systems) to ophthalmology practices and ASCs, then generating recurring revenue from single-use procedural devices and consumables. The OMNI system addresses canaloplasty and trabeculotomy for glaucoma patients, competing in the $1B+ MIGS market against Alcon, Glaukos, and Ivantis. Pricing power derives from procedural reimbursement codes (CPT codes for MIGS procedures typically reimburse $800-1,500), clinical outcomes data, and surgeon training/loyalty. The company's 85.5% gross margin reflects low COGS for disposable devices versus high R&D and sales force investments required for market penetration.
OMNI procedure volume growth and installed base expansion (number of active accounts performing procedures)
TearCare system placements and utilization rates (procedures per system per month)
Clinical trial readouts and FDA regulatory milestones for pipeline indications
Reimbursement policy changes affecting MIGS procedure codes or dry eye treatment coverage
Quarterly revenue beat/miss versus consensus estimates given high growth expectations
Cash burn rate and runway to profitability or need for additional financing
Reimbursement compression risk as CMS and private payers scrutinize MIGS procedure coding and bundling with cataract surgery; potential reclassification could reduce procedure economics
Clinical efficacy challenges if long-term outcomes data fails to demonstrate sustained IOP reduction versus traditional glaucoma surgeries or newer drug delivery systems
Regulatory pathway uncertainty for pipeline products and international expansion requiring CE Mark and country-specific approvals
Intense competition from well-capitalized incumbents (Alcon's iStent franchise, Glaukos' iStent infinite, J&J's trabecular micro-bypass platforms) with established surgeon relationships and broader product portfolios
Technology leapfrog risk from next-generation sustained-release drug delivery systems (bimatoprost implants, travoprost inserts) that could reduce surgical intervention rates
Commoditization pressure as MIGS devices proliferate and differentiation narrows, potentially compressing ASPs and margins
Negative operating cash flow of approximately $20M annually creates cash burn requiring either path to profitability or additional capital raises; dilution risk to existing shareholders
Limited financial flexibility given small market cap ($300M) and negative earnings; acquisition currency is impaired for potential M&A consolidation
Going concern risk if revenue growth stalls below 15-20% annually while operating losses persist at current levels; estimated 2-3 year runway based on current cash position and burn rate
moderate - Elective ophthalmic procedures exhibit some economic sensitivity as patients may defer cataract surgery (often bundled with MIGS) or dry eye treatments during recessions. However, glaucoma progression creates clinical urgency that limits deferral rates. Medicare coverage (65+ demographic represents 70%+ of glaucoma patients) provides downside protection versus purely cosmetic procedures. ASC utilization rates correlate with consumer confidence and employment-linked insurance coverage.
Rising interest rates create multiple headwinds: (1) Higher discount rates compress valuation multiples for unprofitable growth companies, particularly impactful given negative FCF and -8% FCF yield; (2) Increased financing costs for ASCs and ophthalmology practices may slow capital equipment purchases; (3) Competition for investor capital shifts toward profitable businesses as cost of capital rises. The company's 9.60x current ratio provides liquidity buffer, but eventual need for growth capital becomes more expensive in higher rate environment.
Minimal direct credit exposure. Revenue is primarily fee-for-service through Medicare/commercial insurance reimbursement rather than extended payment terms. Customer base (ophthalmologists, ASCs) exhibits low default risk. Company's own credit profile (0.63 debt/equity) is manageable but negative cash flow creates refinancing risk if capital markets tighten.
growth - Attracts speculative growth investors and healthcare-focused funds willing to accept deep losses for potential market share gains in underpenetrated MIGS market. The 103% one-year return despite negative fundamentals indicates momentum/technical trading activity. Not suitable for value or income investors given negative earnings, no dividend, and uncertain path to profitability. Requires 3-5 year investment horizon for commercial execution story to play out.
high - Small-cap medical device stock with binary clinical/regulatory catalysts, quarterly earnings volatility, and low institutional ownership creates high beta (estimated 1.5-2.0x market). Recent 3-month -23% drawdown followed by 6-month +28% gain demonstrates extreme price swings. Options market typically prices 60-80% implied volatility around earnings events.
